Particle Radiation Therapy for Gastrointestinal Cancers.

Abstract:

:Particle irradiation of cancerous disease has gained great traction in recent years. The ability for particle therapy centers to deliver radiation with a highly conformal dose distribution while maintaining minimal exit or excess dose delivered to normal tissue, coupled with various biological advantages particularly found with heavy-ion beams, enables treatment of diseases inapproachable with conventional radiotherapy. Here, we present a review of the current status of particle therapy with regard to cancers of the gastrointestinal tract, including esophagus, liver, pancreas, and recurrent rectal cancer.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Shinoto M,Ebner DK,Yamada S

doi

10.1007/s11912-016-0499-8

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

17

issue

3

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-016-0499-8

journal_volume

18

pub_type

杂志文章,评审
  • Targeting breast cancer with CDK inhibitors.

    abstract::Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0443-3

    authors: Mayer EL

    更新日期:2015-01-01 00:00:00

  • Telemedicine and Palliative Care: an Increasing Role in Supportive Oncology.

    abstract::With the emergence of telemedicine as a routine form of care in various venues, the opportunities to use technology to care for the most vulnerable, most ill cancer patients are extremely appealing. Increasingly, evidence supports early integration of palliative care with standard oncologic care, supported by recent N...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0600-y

    authors: Worster B,Swartz K

    更新日期:2017-06-01 00:00:00

  • The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

    abstract::The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0012-z

    authors: Ruymann FB

    更新日期:2003-11-01 00:00:00

  • Opioids and Chronic Pain: Where Is the Balance?

    abstract::Chronic opioid therapy (defined as greater than 3 months on opioids) is a common practice for those with non-cancer pain, cancer survivors with treatment-related pain, and individuals with cancer undergoing disease-modifying therapy with a survival that can be for a year or more. Recent studies have found unique long-...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0558-1

    authors: Davis MP,Mehta Z

    更新日期:2016-12-01 00:00:00

  • Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

    abstract:PURPOSE OF REVIEW:The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS:In low-risk patients, RT could be omitted but, at ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0592-7

    authors: Filippi AR,Levis M,Parikh R,Hoppe B

    更新日期:2017-05-01 00:00:00

  • Immunotherapy in Anal Cancer.

    abstract:PURPOSE OF REVIEW:Standard treatment for early-stage squamous cell cancer of the anal canal (SCCA) includes concurrent chemotherapy and radiation to achieve curative intent. Treatment options are limited, however, especially with locoregional disease relapse occurring in 20-30% of patients and about 10-30% of patients ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00946-3

    authors: Phuong L,Rajdev L

    更新日期:2020-07-11 00:00:00

  • Management of metastatic melanoma patients with brain metastases.

    abstract::Brain metastases seem to be an almost inevitable complication in patients with metastatic melanoma. Except for the rare patients who can undergo successful surgical resection of brain metastases, current management strategies do not appear adequate and result in a poor outcome (median survival, 2-4 months). In recent ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0056-6

    authors: Majer M,Samlowski WE

    更新日期:2007-09-01 00:00:00

  • Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

    abstract::Results of treatment for patients with non-Hodgkin's lymphomas have significantly improved over the last decade, especially following the discovery that anti-CD20 antibody therapy can significantly change the outlook for patients with both aggressive and indolent lymphomas. Although investigators have previously attem...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0128-x

    authors: Hagemeister FB

    更新日期:2010-11-01 00:00:00

  • Molecular diagnosis in lymphoma.

    abstract::The evolution of our ability to diagnose and classify lymphomas in an increasingly refined manner has paralleled the development of novel technologic approaches, with contemporary practice dependent upon the harnessing of a plethora of data that include microscopic, immunophenotypic, and genetic information. Although ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0063-9

    authors: Bagg A

    更新日期:2004-09-01 00:00:00

  • Prevention of radiation-induced mucositis.

    abstract::Radiation-induced mucositis is an important dose-limiting acute side effect associated with the treatment of tumors of the upper aerodigestive tract. The toxicity of radiation therapy increases with prior or concurrent administration of some chemotherapeutic agents. Pretreatment eradication of infection, maintenance o...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0043-2

    authors: Johnson JT

    更新日期:2001-01-01 00:00:00

  • Current management of anal canal cancer.

    abstract::Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0027-1

    authors: Czito BG,Willett CG

    更新日期:2009-05-01 00:00:00

  • Management of gynecological cancers during pregnancy.

    abstract::The diagnosis of a gynecological malignancy during pregnancy is rare but not uncommon. Cancer treatment during pregnancy is possible, but both maternal and fetal interests need to be respected. Different treatment plans may be justifiable and multidisciplinary treatment is advised. Clinical trials are virtually imposs...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-014-0415-z

    authors: Han SN,Verheecke M,Vandenbroucke T,Gziri MM,Van Calsteren K,Amant F

    更新日期:2014-12-01 00:00:00

  • Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.

    abstract::The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafe...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-013-0292-x

    authors: Zaki K,Aslam S,Eisen T

    更新日期:2013-04-01 00:00:00

  • Head and neck cancer immunotherapy: clinical evaluation.

    abstract::Overall survival for patients with squamous cell carcinoma of the head and neck (SCCHN) has not improved appreciably over the past few decades. Because standard treatments have not controlled this disease with sufficiently high success rates, novel therapeutic approaches, such as immunotherapy, are under investigation...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0025-8

    authors: Leibowitz MS,Nayak JV,Ferris RL

    更新日期:2008-03-01 00:00:00

  • Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

    abstract::The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0249-5

    authors: Mehnert JM,Kluger HM

    更新日期:2012-10-01 00:00:00

  • Proton beam radiation therapy for head and neck malignancies.

    abstract::Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0089-0

    authors: Frank SJ,Selek U

    更新日期:2010-05-01 00:00:00

  • A role for antiangiogenic therapy in breast cancer.

    abstract::The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical tr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-996-0008-6

    authors: Moses MA,Harper J,Fernández CA

    更新日期:2004-01-01 00:00:00

  • Molecular genetics of pediatric central nervous system tumors.

    abstract::Recent advances in molecular biology have enhanced our understanding of the pathogenesis of brain tumors, particularly in children. The use of molecular diagnostic tools is quickly becoming a standard component in the diagnosis and classification of brain tumors in children, in addition to providing insight leading to...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0070-0

    authors: Ullrich NJ,Pomeroy SL

    更新日期:2006-11-01 00:00:00

  • Targeted therapy for malignant melanoma.

    abstract::There has been much development in the field of targeted therapy for melanoma stemming from efforts to decrease treatment-related toxicities and enhance specific cytotoxicity. This review focuses on three modalities of targeted melanoma therapy based on the biology of the targeting mechanism. The first of these modali...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0088-2

    authors: Brown CK,Kirkwood JM

    更新日期:2001-07-01 00:00:00

  • Single-Cell RNA-Sequencing in Glioma.

    abstract:PURPOSE OF REVIEW:In this review, we seek to summarize the literature concerning the use of single-cell RNA-sequencing for CNS gliomas. RECENT FINDINGS:Single-cell analysis has revealed complex tumor heterogeneity, subpopulations of proliferating stem-like cells and expanded our view of tumor microenvironment influenc...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0673-2

    authors: Johnson E,Dickerson KL,Connolly ID,Hayden Gephart M

    更新日期:2018-04-10 00:00:00

  • Therapeutic advances for glioblastoma multiforme: current status and future prospects.

    abstract::Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/BF02951428

    authors: Robins HI,Chang S,Butowski N,Mehta M

    更新日期:2007-01-01 00:00:00

  • The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery.

    abstract:PURPOSE OF REVIEW:The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires-completed and reviewed with patients during care delivery-are poised to play a large role in this guideline because they provide a more comprehensive underst...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0571-z

    authors: Stover AM,Basch EM

    更新日期:2017-02-01 00:00:00

  • Review of neoadjuvant chemotherapy and trachelectomy: which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery?

    abstract::The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0446-0

    authors: Robova H,Rob L,Halaska MJ,Pluta M,Skapa P

    更新日期:2015-01-01 00:00:00

  • Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

    abstract:PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0694-x

    authors: Rhodes J,Mato A,Sharman JP

    更新日期:2018-04-11 00:00:00

  • Prodrug/drug sensitivity gene therapy: current status.

    abstract::The prodrug strategy has its own particular real and theoretic obstacles. Clinical strategies and research efforts have tried to approach these problems. The bystander effect, whereby nontransduced cells are affected by simple proximity to those that have received the novel gene, has enabled many prodrug systems to be...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0006-z

    authors: Smythe WR

    更新日期:2000-01-01 00:00:00

  • The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies.

    abstract::HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive res...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0073-9

    authors: Perez EA

    更新日期:2001-11-01 00:00:00

  • Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

    abstract:PURPOSE OF REVIEW:Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety profiles, financial...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00989-6

    authors: Tabbò F,Passiglia F,Novello S

    更新日期:2021-01-02 00:00:00

  • Fertility preservation and management of gonadal failure associated with lymphoma therapy.

    abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0039-6

    authors: Howell SJ,Shalet SM

    更新日期:2002-09-01 00:00:00

  • Hepatitis c and lymphoma.

    abstract::Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands. Experimental data further support this hypothesis....

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0090-0

    authors: Silvestri F,Sperotto A,Fanin R

    更新日期:2000-03-01 00:00:00

  • Aflibercept--a decoy VEGF receptor.

    abstract::Aflibercept (known as ziv-aflibercept in the USA and sold under the trade name Zaltrap®) is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factors A and B and placental growth factor. Its unique mechanism of action with respect to o...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0368-7

    authors: Ciombor KK,Berlin J

    更新日期:2014-02-01 00:00:00